MarketPeel
Insider Trading Intelligence
JL

John A. Lewicki

MREO
CHIEF SCIENTIFIC OFFICER · MEREO BIOPHARMA GROUP PLC · CIK 0001553352
FILING MIX · LIFETIME62%/38%
BUYS
8
SELLS
5
TOTAL VALUE
$153.9K
COMPANIES
1
ACTIVE SINCE
Jan 2024
HOLDINGS NOW
145,000
AVG SELL PX
$3.81
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by John A. Lewicki, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+75.00%-0.44%+1.35%-1.79%-2.16%
14d4+50.00%+2.04%+2.40%-0.36%-0.07%
30d4+25.00%+9.73%+1.72%+8.01%+8.95%
60d4+50.00%+17.71%+4.98%+12.72%+12.45%
90d4+50.00%+1.94%+6.69%-4.75%-4.86%
180d4+100.00%-22.37%+4.93%-27.30%-26.87%
1y4+100.00%-38.67%+15.62%-54.30%-53.93%
2y4(2 pending)+100.00%-90.78%+34.59%-125.37%-125.37%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MREO · 145,000 shares · as of Feb 1, 2026
036,25072,500108,750145,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 8 buys / 5 sellsCOVERAGE · 9 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASEGRANT
Stock grant
46,63746,637Feb 1, 2026Feb 2, 2026View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASEGRANT
Stock grant
139,913139,913Feb 1, 2026Feb 2, 2026View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASEGRANT
Stock grant
145,000145,000Feb 1, 2026Feb 2, 2026View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASEGRANT
Stock grant
116,000116,000Jan 25, 2025Jan 28, 2025View →
MREO
MEREO BIOPHARMA GROUP PLC
SALE
Chief Scientific Officer
10,937$4.22$46.2K78,630Sep 13, 2024Sep 16, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
SALE
Chief Scientific Officer
5,212$4.47$23.3K89,567Sep 12, 2024Sep 16, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASE
Chief Scientific Officer
46,00094,779Sep 11, 2024Sep 13, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
SALE
Chief Scientific Officer
46,0000Sep 11, 2024Sep 13, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
SALE
Chief Scientific Officer
16,808$3.39$57.0K48,779Jun 26, 2024Jun 27, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
SALE
Chief Scientific Officer
7,416$3.69$27.4K65,587Jun 25, 2024Jun 27, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASE
Chief Scientific Officer
69,00046,000Jun 21, 2024Jun 25, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASE
Chief Scientific Officer
69,00073,003Jun 21, 2024Jun 25, 2024View →
MREO
MEREO BIOPHARMA GROUP PLC
PURCHASEGRANT
Stock grant
137,000137,000Jan 25, 2024Jan 26, 2024View →
Other insiders · MREO
Loading peer insiders…
About this filer
CIK 0001553352
ROLE
Chief Scientific Officer
PRIMARY
MREO
COMPANIES
1
ACTIVE SINCE
Jan 2024
MARKETPEEL · /INSIDER/0001553352DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback